US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
DE69433036T2
(de)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Aminoderivatisierte nukleoside und oligonukleoside
|
EP0714907A1
(de)
*
|
1994-11-30 |
1996-06-05 |
F. Hoffmann-La Roche Ag |
Oligonukleotide mit Amid-Hauptkette
|
DE59607750D1
(de)
*
|
1995-03-13 |
2001-10-31 |
Aventis Pharma Gmbh |
Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
|
WO1996030383A1
(de)
*
|
1995-03-24 |
1996-10-03 |
Christian Noe |
Nukleinsäure-polyester-polyamide
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US20020028442A1
(en)
*
|
1997-05-09 |
2002-03-07 |
Christian Miculka |
Novel substance library and supramolecular complexes produced therewith
|
US20040161844A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US20040171028A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5760013A
(en)
*
|
1996-08-21 |
1998-06-02 |
National Science Council |
Thymidylate analogs and the use thereof
|
CA2294988C
(en)
|
1997-07-01 |
2015-11-24 |
Isis Pharmaceuticals Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
CA2329130A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
JP2002515514A
(ja)
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの局所送逹のための組成物及び方法
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
US6867294B1
(en)
*
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
IL142094A0
(en)
*
|
1998-09-29 |
2002-03-10 |
Gamida Cell Ltd |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6127124A
(en)
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US7534605B2
(en)
*
|
1999-06-08 |
2009-05-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6593466B1
(en)
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
US7668658B2
(en)
|
1999-10-13 |
2010-02-23 |
Sequenom, Inc. |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
AU5340801A
(en)
*
|
2000-04-13 |
2001-10-30 |
Thomas N Wight |
Therapeutic compounds and methods
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US6686188B2
(en)
|
2000-05-26 |
2004-02-03 |
Amersham Plc |
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
|
US6656700B2
(en)
|
2000-05-26 |
2003-12-02 |
Amersham Plc |
Isoforms of human pregnancy-associated protein-E
|
US6958214B2
(en)
|
2000-07-10 |
2005-10-25 |
Sequenom, Inc. |
Polymorphic kinase anchor proteins and nucleic acids encoding the same
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
EP2336166A1
(de)
|
2000-10-12 |
2011-06-22 |
University Of Rochester |
Zusammensetzungen die die Proliferation von Krebszellen hemmen
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US6573051B2
(en)
*
|
2001-03-09 |
2003-06-03 |
Molecular Staging, Inc. |
Open circle probes with intramolecular stem structures
|
WO2002072790A2
(en)
|
2001-03-14 |
2002-09-19 |
Myriad Genetics, Inc |
Tsg101-gag interaction and use thereof
|
CA2633595A1
(en)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP2221376B1
(de)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US20030109476A1
(en)
*
|
2001-08-07 |
2003-06-12 |
Kmiec Eric B. |
Compositions and methods for the prevention and treatment of Huntington's disease
|
US20040096880A1
(en)
*
|
2001-08-07 |
2004-05-20 |
Kmiec Eric B. |
Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
|
ATE486092T1
(de)
|
2001-09-18 |
2010-11-15 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
EP1465982A4
(de)
*
|
2002-01-25 |
2006-06-07 |
Gamida Cell Ltd |
Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
AU2003231912A1
(en)
*
|
2002-06-12 |
2003-12-31 |
Tel Aviv Medical Center Research Development Fund |
Methods of detecting and treating prostate cancer
|
EP2116604A1
(de)
|
2002-08-05 |
2009-11-11 |
University of Rochester |
Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
|
EP2330194A3
(de)
|
2002-09-13 |
2011-10-12 |
Replicor, Inc. |
Nicht-sequenzkomplementäre antivirale Oligonukleotide
|
JP2006500030A
(ja)
*
|
2002-09-20 |
2006-01-05 |
イェール ユニバーシティ |
リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
|
EP1549767A4
(de)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation der expression von forkhead-box o1a
|
AU2003290596B2
(en)
|
2002-11-05 |
2011-05-12 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004044138A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
ES2417879T3
(es)
|
2002-11-13 |
2013-08-09 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
US20060009378A1
(en)
|
2002-11-14 |
2006-01-12 |
Itshak Golan |
Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
|
AU2003295576B2
(en)
|
2002-11-15 |
2011-03-17 |
Eisai, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
ES2392511T3
(es)
|
2002-11-15 |
2012-12-11 |
Musc Foundation For Research Development |
Moduladores de complemento dianas sobre el receptor 2 de complemento
|
CA2507044A1
(en)
|
2002-11-21 |
2004-06-10 |
Mary Lucero |
Purinergic modulation of smell
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US20040121338A1
(en)
*
|
2002-12-19 |
2004-06-24 |
Alsmadi Osama A. |
Real-time detection of rolling circle amplification products
|
JP4886298B2
(ja)
|
2002-12-20 |
2012-02-29 |
キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
核酸増幅
|
US9487823B2
(en)
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
WO2004072284A1
(en)
|
2003-02-11 |
2004-08-26 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
WO2004076621A2
(en)
|
2003-02-27 |
2004-09-10 |
Yeda Research And Development Co. Ltd. |
Compositions of nucleic acids for treating and detecting influenza virus
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
DK2336317T3
(da)
|
2003-06-13 |
2019-12-16 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
BRPI0413930A
(pt)
|
2003-09-18 |
2006-10-24 |
Isis Pharmaceuticals Inc |
composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste
|
EP1677822B1
(de)
|
2003-09-18 |
2014-04-23 |
Isis Pharmaceuticals, Inc. |
4'-thionucleoside und oligomere verbindungen
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
CA2546285C
(en)
|
2003-11-17 |
2015-12-29 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US7842459B2
(en)
|
2004-01-27 |
2010-11-30 |
Compugen Ltd. |
Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
WO2005097817A2
(en)
|
2004-04-05 |
2005-10-20 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
CA2564251C
(en)
|
2004-05-21 |
2018-04-10 |
The Uab Research Foundation |
Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1799812A4
(de)
|
2004-09-16 |
2009-09-09 |
Gamida Cell Ltd |
Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
|
TR201907874T4
(tr)
|
2004-09-23 |
2019-06-21 |
Arc Medical Devices Inc |
Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler.
|
EP1843819A2
(de)
*
|
2004-11-15 |
2007-10-17 |
Obe Therapy Biotechnology S.A.S. |
Verfahren zur reduzierung von körperfett
|
US20080260637A1
(en)
|
2004-11-17 |
2008-10-23 |
Dalia Dickman |
Methods of Detecting Prostate Cancer
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
EP1863908B1
(de)
|
2005-04-01 |
2010-11-17 |
Qiagen GmbH |
Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
|
JP5329949B2
(ja)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
|
US20090209621A1
(en)
|
2005-06-03 |
2009-08-20 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
CN101273130B
(zh)
*
|
2005-07-07 |
2012-05-30 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
用于下调h19的核酸物质及其使用方法
|
EP2239327B1
(de)
|
2005-08-11 |
2015-02-25 |
Synthetic Genomics, Inc. |
Verfahren zur In-Vitro-Rekombination
|
KR20080036646A
(ko)
|
2005-08-17 |
2008-04-28 |
메덱시스 에스.에이. |
Ck19 발현 측정을 위한 조성물 및 방법
|
EP2338991B1
(de)
|
2005-08-29 |
2017-01-18 |
Regulus Therapeutics Inc. |
Verfahren für MIR-122a-Modulation
|
EP2338992A3
(de)
|
2005-08-29 |
2011-10-12 |
Regulus Therapeutics, Inc |
Antisense-verbindungen mit verbesserter anti-mikrorna-aktivität
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
IL172297A
(en)
|
2005-10-03 |
2016-03-31 |
Compugen Ltd |
Soluble vegfr-1 variants for the diagnosis of preeclampsia
|
WO2007047512A2
(en)
|
2005-10-14 |
2007-04-26 |
Musc Foundation For Research Development |
Inhibition of pax2 by defb1 induction as a therapy for cancer
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP1941059A4
(de)
|
2005-10-28 |
2010-11-03 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der expression des huntingtin-gens
|
EP1945270B1
(de)
|
2005-11-09 |
2011-05-25 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
|
CA2630602A1
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
JP2009524411A
(ja)
*
|
2005-12-21 |
2009-07-02 |
イェール ユニバーシティー |
リボスイッチの調節に関連した方法および組成物
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
EP1973945A4
(de)
|
2006-01-16 |
2009-11-18 |
Compugen Ltd |
Neue nukleotid- und aminosäuresequenzen und verfahren zu deren anwendung in der diagnose
|
EP1984499B1
(de)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulation von mikro-rnas
|
EP1984381B1
(de)
*
|
2006-01-27 |
2010-09-29 |
Isis Pharmaceuticals, Inc. |
6-modifizierte bicyclische nukleinsäureanaloga
|
CN101448849B
(zh)
|
2006-03-31 |
2013-08-21 |
阿尔尼拉姆医药品有限公司 |
抑制Eg5基因表达的组合物和方法
|
AU2007245599B2
(en)
|
2006-05-03 |
2012-05-10 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
JP5825754B2
(ja)
|
2006-05-05 |
2015-12-02 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Apobの発現を調節するための化合物および方法
|
NZ572666A
(en)
|
2006-05-11 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
|
ES2389737T3
(es)
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en 5'
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
WO2008033866A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Yale University |
Methods and compositions for the use of lysine riboswitches
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
CA2927045A1
(en)
|
2006-10-03 |
2008-04-10 |
Muthiah Manoharan |
Lipid containing formulations
|
EP2081596A4
(de)
|
2006-10-06 |
2010-07-21 |
Univ Utah Res Found |
Verfahren zum nachweis von augenkrankheiten und pathologischen zuständen und behandlung dafür
|
US8999317B2
(en)
|
2006-11-01 |
2015-04-07 |
University Of Rochester |
Methods and compositions related to the structure and function of APOBEC3G
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
MX2009005527A
(es)
*
|
2006-11-27 |
2009-06-08 |
Isis Pharmaceuticals Inc |
Metodos para el tratamiento de hipercolesterolemia.
|
KR20090089462A
(ko)
|
2006-12-11 |
2009-08-21 |
유니버시티 오브 유타 리써치 파운데이션 |
병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
|
US20100129358A1
(en)
|
2006-12-22 |
2010-05-27 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
EP2111450A2
(de)
*
|
2007-01-16 |
2009-10-28 |
Yissum Research Development Company of the Hebrew University of Jerusalem |
Nukleinsäurekonstrukte und verfahren zur spezifischen stilllegung von h19
|
WO2008093331A1
(en)
*
|
2007-01-29 |
2008-08-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Antibody conjugates for circumventing multi-drug resistance
|
EP2121987B1
(de)
|
2007-02-09 |
2012-06-13 |
Northwestern University |
Partikel zur erkennung intrazellulärer ziele
|
EP2129803A4
(de)
*
|
2007-02-27 |
2010-11-03 |
Univ Northwestern |
Anbringung von molekülen an nanopartikeln
|
CN101801185A
(zh)
|
2007-03-22 |
2010-08-11 |
耶鲁大学 |
与控制可变剪接的核糖开关有关的方法和组合物
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
AP2014007971A0
(en)
|
2007-03-29 |
2014-09-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
US20110091377A1
(en)
|
2007-05-11 |
2011-04-21 |
The Johns Hopkins University |
Biomarkers for melanoma
|
EP2164994A4
(de)
*
|
2007-05-29 |
2010-07-21 |
Univ Yale Inc |
Verfahren und zusammensetzungen in verbindung mit riboswitches zu steuerung von alternativer spleissung und rna-verarbeitung
|
EP2164996A4
(de)
|
2007-05-29 |
2010-07-14 |
Univ Yale |
Riboswitches sowie verfahren und zusammensetzungen zur verwendung von und mit riboswitches
|
DK2826863T3
(en)
|
2007-05-30 |
2017-12-04 |
Univ Northwestern |
NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
AU2008270209B2
(en)
|
2007-07-05 |
2012-05-17 |
Arrowhead Pharmaceuticals, Inc. |
dsRNA for treating viral infection
|
ATE538127T1
(de)
*
|
2007-07-05 |
2012-01-15 |
Isis Pharmaceuticals Inc |
6-disubstituierte bicyclische nukleinsäureanaloga
|
CN101821277B
(zh)
|
2007-08-15 |
2014-05-07 |
Isis制药公司 |
四氢吡喃核酸类似物
|
WO2009032693A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
SI2769729T1
(sl)
|
2007-09-04 |
2019-06-28 |
Compugen Ltd. |
Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
|
WO2009039466A1
(en)
|
2007-09-20 |
2009-03-26 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
JP2010539978A
(ja)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
マイクロ−rnaおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
US8916531B2
(en)
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
WO2009067647A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
CA3044134A1
(en)
|
2008-01-02 |
2009-07-09 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
US8530640B2
(en)
|
2008-02-07 |
2013-09-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
CN102016036B
(zh)
|
2008-02-11 |
2015-04-08 |
阿克赛医药公司 |
经修饰的RNAi多核苷酸及其用途
|
CA2716793A1
(en)
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
EP2282744B1
(de)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit trizyklischen nukleosiden und anwendungsverfahren dafür
|
EP2285819B1
(de)
*
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
|
PL2281042T3
(pl)
|
2008-04-18 |
2016-01-29 |
Baxter Int |
Kompozycja na bazie mikrosfer do zapobiegania i/lub cofania nowego przypadku cukrzycy autoimmunologicznej
|
US20090274696A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Wyeth |
Methods for treating inflammation
|
KR20110017005A
(ko)
*
|
2008-07-15 |
2011-02-18 |
에프. 호프만-라 로슈 아게 |
Tgf-베타 수용체 유전자 발현 억제용 조성물 및 방법
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
JP5420668B2
(ja)
|
2008-08-25 |
2014-02-19 |
エクスカリアード・ファーマシューティカルズ,インコーポレイテッド |
結合組織成長因子を対象とするアンチセンスオリゴヌクレオチドおよびその使用
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
AU2009293658A1
(en)
|
2008-09-22 |
2010-03-25 |
James Cardia |
Reduced size self-delivering RNAi compounds
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
EP2356129B1
(de)
*
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituierte alpha-l-bicyclische nukleoside
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
CN103820450B
(zh)
|
2008-10-15 |
2018-08-21 |
Ionis制药公司 |
因子11表达的调节
|
US8168775B2
(en)
|
2008-10-20 |
2012-05-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
JP5763539B2
(ja)
|
2008-10-24 |
2015-08-12 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
5’及び2’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
CA2743249A1
(en)
*
|
2008-11-17 |
2010-05-20 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of factor vii genes
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
DK2365803T3
(en)
|
2008-11-24 |
2018-01-22 |
Univ Northwestern |
POLYVALENT RNA NANOPARTICLE COMPOSITIONS
|
WO2010061393A1
(en)
|
2008-11-30 |
2010-06-03 |
Compugen Ltd. |
He4 variant nucleotide and amino acid sequences, and methods of use thereof
|
JP6099868B2
(ja)
|
2008-12-04 |
2017-03-22 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるサーチュイン1関連疾患の治療
|
WO2010065792A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
EP2370582B1
(de)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
|
WO2010064248A2
(en)
|
2008-12-05 |
2010-06-10 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and treating motor neuron diseases
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
AU2009335740B2
(en)
|
2008-12-17 |
2016-04-21 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
KR101546673B1
(ko)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
전자 사진용 토너 및 그의 제조방법
|
EP3243504A1
(de)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Verbesserte lipidformulierung
|
CN102307996A
(zh)
|
2009-02-03 |
2012-01-04 |
弗·哈夫曼-拉罗切有限公司 |
用于抑制ptp1b基因表达的组合物和方法
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
EP3424939A1
(de)
|
2009-03-02 |
2019-01-09 |
Alnylam Pharmaceuticals Inc. |
Chemische nukleinsäuremodifikationen
|
JP6250263B2
(ja)
|
2009-03-04 |
2017-12-20 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるsirt1関連疾患の治療
|
CN104922699B
(zh)
|
2009-03-12 |
2020-07-24 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
AU2010237001B2
(en)
|
2009-04-15 |
2016-07-07 |
Northwestern University |
Delivery of oligonucleotide-functionalized nanoparticles
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
US8318690B2
(en)
|
2009-05-01 |
2012-11-27 |
Curna, Inc. |
Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
|
EP3097908A1
(de)
|
2009-05-05 |
2016-11-30 |
Arbutus Biopharma Corporation |
Fettzusammensetzungen
|
US20100285112A1
(en)
|
2009-05-05 |
2010-11-11 |
Tatiana Novobrantseva |
Methods of delivering oligonucleotides to immune cells
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
SG176099A1
(en)
*
|
2009-05-15 |
2011-12-29 |
Hoffmann La Roche |
Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
|
WO2010132665A1
(en)
|
2009-05-15 |
2010-11-18 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
EP2446036B1
(de)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
US8927513B2
(en)
|
2009-07-07 |
2015-01-06 |
Alnylam Pharmaceuticals, Inc. |
5′ phosphate mimics
|
WO2011005861A1
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide end caps
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
US20120157324A1
(en)
|
2009-08-17 |
2012-06-21 |
Yale University |
Methylation biomarkers and methods of use
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
CN105368836A
(zh)
|
2009-10-14 |
2016-03-02 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
用于控制蜂中的瓦螨的组合物
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
WO2011056687A2
(en)
|
2009-10-27 |
2011-05-12 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
DK2494075T3
(en)
|
2009-10-30 |
2018-07-23 |
Univ Northwestern |
TABLE-MANAGED NANOCONJUGATES
|
WO2011056215A1
(en)
|
2009-11-03 |
2011-05-12 |
Landers James P |
Versatile, visible method for detecting polymeric analytes
|
AR078921A1
(es)
*
|
2009-11-09 |
2011-12-14 |
Hoffmann La Roche |
Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
|
WO2011058555A1
(en)
|
2009-11-12 |
2011-05-19 |
Yeda Research And Development Co. Ltd. |
A method of editing dna in a cell and constructs capable of same
|
KR101944119B1
(ko)
|
2009-11-13 |
2019-01-30 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
|
WO2011063403A1
(en)
|
2009-11-23 |
2011-05-26 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(hgf)에 대한 천연 안티센스 전사체의 억제에 의한 hgf 관련 질환의 치료
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
EP2521785B1
(de)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2524042A2
(de)
|
2010-01-12 |
2012-11-21 |
Yale University |
Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
WO2011097407A1
(en)
|
2010-02-04 |
2011-08-11 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
TW201129365A
(en)
|
2010-02-05 |
2011-09-01 |
Hoffmann La Roche |
Compositions and methods for inhibiting expression of IKK2 genes
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
MX2012010479A
(es)
|
2010-03-08 |
2012-10-09 |
Monsanto Technology Llc |
Moleculas polinucleotidicas para regulacion genetica en plantas.
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
ES2743600T3
(es)
|
2010-03-12 |
2020-02-20 |
Brigham & Womens Hospital Inc |
Métodos de tratamiento de los trastornos inflamatorios vasculares
|
WO2011113054A2
(en)
|
2010-03-12 |
2011-09-15 |
Aurasense Llc |
Crosslinked polynucleotide structure
|
WO2011113015A2
(en)
|
2010-03-12 |
2011-09-15 |
Avi Biopharma, Inc. |
Antisense modulation of nuclear hormone receptors
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
KR101852210B1
(ko)
|
2010-03-24 |
2018-04-25 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 rna 간섭
|
EP2550001B1
(de)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna-interferenz bei augenerkrankungen
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
WO2011120046A2
(en)
|
2010-03-26 |
2011-09-29 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
CA2792291A1
(en)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
CA2795281A1
(en)
|
2010-04-09 |
2011-10-13 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
JP6005628B2
(ja)
|
2010-04-28 |
2016-10-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
|
EP2625186B1
(de)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
KR20180026798A
(ko)
|
2010-04-29 |
2018-03-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
트랜스티레틴 발현의 조절
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
CA3090304A1
(en)
|
2010-05-13 |
2011-11-17 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
RU2585229C2
(ru)
|
2010-05-26 |
2016-05-27 |
Курна, Инк. |
Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
|
WO2011150226A1
(en)
|
2010-05-26 |
2011-12-01 |
Landers James P |
Method for detecting nucleic acids based on aggregate formation
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2580228B1
(de)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
|
WO2011156713A1
(en)
|
2010-06-11 |
2011-12-15 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
US9168297B2
(en)
|
2010-06-23 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (NRG-1)
|
CN107441480A
(zh)
|
2010-06-30 |
2017-12-08 |
卡姆普根有限公司 |
多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途
|
US20130143955A1
(en)
|
2010-08-09 |
2013-06-06 |
Yale University |
Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
|
WO2012038956A1
(en)
|
2010-09-20 |
2012-03-29 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Method of treating neurodegenerative diseases
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
EP2627766B1
(de)
|
2010-10-17 |
2016-05-25 |
Yeda Research and Development Co. Ltd. |
Verfahren und zusammensetzungen zur behandlung von insulinassoziierten erkrankungen
|
EP3434772A3
(de)
|
2010-10-18 |
2019-03-20 |
Arrowhead Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
RU2608493C2
(ru)
|
2010-11-23 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
EP2663323B1
(de)
|
2011-01-14 |
2017-08-16 |
The General Hospital Corporation |
Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
|
CN103391777A
(zh)
|
2011-02-02 |
2013-11-13 |
普林斯顿大学理事会 |
作为病毒产生调节剂的去乙酰化酶调节剂
|
CN103635197A
(zh)
|
2011-02-02 |
2014-03-12 |
埃克斯利尔德生物制药公司 |
使用靶向结缔组织生长因子(ctgf)的反义化合物治疗疤痕疙瘩或肥大性疤痕的方法
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
MX360349B
(es)
|
2011-03-29 |
2018-10-30 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
|
EP2694660B1
(de)
|
2011-04-03 |
2018-08-08 |
The General Hospital Corporation |
Effiziente in-vivo-proteinexpression mittels modifizierter rna (mod-rna)
|
WO2012140627A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
TWI678375B
(zh)
|
2011-06-09 |
2019-12-01 |
可娜公司 |
藉由抑制共濟蛋白(frataxin,fxn)之天然反股轉錄本治療fxn相關疾病
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
AU2012272860A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
|
EP3597750B1
(de)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
MX342731B
(es)
|
2011-06-30 |
2016-10-11 |
Arrowhead Res Corp |
Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
WO2013018060A2
(en)
|
2011-08-04 |
2013-02-07 |
Yeda Research And Development Co. Ltd. |
Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
|
US10829828B2
(en)
|
2011-09-13 |
2020-11-10 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US9840715B1
(en)
|
2011-09-13 |
2017-12-12 |
Monsanto Technology Llc |
Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
|
WO2013040057A1
(en)
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US9416363B2
(en)
|
2011-09-13 |
2016-08-16 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10806146B2
(en)
|
2011-09-13 |
2020-10-20 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
PL2755467T3
(pl)
|
2011-09-13 |
2018-01-31 |
Monsanto Technology Llc |
Sposoby i kompozycje do kontroli chwastów
|
US10760086B2
(en)
|
2011-09-13 |
2020-09-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
UA116090C2
(uk)
|
2011-09-13 |
2018-02-12 |
Монсанто Текнолоджи Ллс |
Спосіб та композиція для боротьби з бур'янами (варіанти)
|
EP2756080B1
(de)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimere oligonukleotidverbindungen
|
JP2014526517A
(ja)
|
2011-09-14 |
2014-10-06 |
ノースウェスタン ユニバーシティ |
血液脳関門を通過することができるナノ抱合体
|
US9920326B1
(en)
|
2011-09-14 |
2018-03-20 |
Monsanto Technology Llc |
Methods and compositions for increasing invertase activity in plants
|
US9580713B2
(en)
|
2011-09-17 |
2017-02-28 |
Yale University |
Fluoride-responsive riboswitches, fluoride transporters, and methods of use
|
AU2012322788B2
(en)
|
2011-10-11 |
2018-01-04 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
AR088322A1
(es)
|
2011-10-14 |
2014-05-28 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
EP2771464B1
(de)
|
2011-10-27 |
2018-03-21 |
Yeda Research and Development Co. Ltd. |
Verfahren zur behandlung von karzinomen
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
BR112014018481A2
(pt)
|
2012-02-01 |
2017-07-04 |
Compugen Ltd |
anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
|
JP6348848B2
(ja)
|
2012-02-13 |
2018-06-27 |
ガミダ セル リミテッド |
間葉系幹細胞の増殖
|
WO2013124816A2
(en)
|
2012-02-22 |
2013-08-29 |
Brainstem Biotec Ltd. |
Generation of neural stem cells and motor neurons
|
WO2013124817A2
(en)
|
2012-02-22 |
2013-08-29 |
Brainstem Biotec Ltd. |
MicroRNAS FOR THE GENERATION OF ASTROCYTES
|
WO2013138536A1
(en)
|
2012-03-13 |
2013-09-19 |
Swift Biosciences, Inc. |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
EP2639238A1
(de)
|
2012-03-15 |
2013-09-18 |
Universität Bern |
Tricyclische Nukleoside und daraus hergestellte oligomere Verbindungen
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
AU2013248981B2
(en)
|
2012-04-20 |
2018-11-29 |
Aptamir Therapeutics, Inc. |
Mirna modulators of thermogenesis
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
DK2850186T3
(en)
|
2012-05-16 |
2019-04-08 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
|
CN104583398A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节基因表达的组合物和方法
|
US10240161B2
(en)
|
2012-05-24 |
2019-03-26 |
A.B. Seeds Ltd. |
Compositions and methods for silencing gene expression
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US20150216892A1
(en)
|
2012-08-03 |
2015-08-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
US9950001B2
(en)
|
2012-08-20 |
2018-04-24 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CA2888264A1
(en)
|
2012-10-18 |
2014-04-24 |
Monsanto Technology Llc |
Methods and compositions for plant pest control
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
AU2013371825B2
(en)
|
2013-01-01 |
2019-10-24 |
A.B. Seeds Ltd. |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
US10683505B2
(en)
|
2013-01-01 |
2020-06-16 |
Monsanto Technology Llc |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
EP2945652B1
(de)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Verfahren zur behandlung cholangiokarzinom
|
US10000767B2
(en)
|
2013-01-28 |
2018-06-19 |
Monsanto Technology Llc |
Methods and compositions for plant pest control
|
KR102190852B1
(ko)
|
2013-01-31 |
2020-12-14 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 커플링 프로토콜을 이용하는 올리고머 화합물의 제조 방법
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
AR095233A1
(es)
|
2013-03-13 |
2015-09-30 |
Monsanto Technology Llc |
Métodos y composiciones para el control de malezas
|
UA123082C2
(uk)
|
2013-03-13 |
2021-02-17 |
Монсанто Текнолоджи Ллс |
Спосіб та гербіцидна композиція для боротьби з видами рослин роду sorghum
|
ES2708650T3
(es)
|
2013-03-14 |
2019-04-10 |
Andes Biotechnologies Global Inc |
Oligonucleótidos antisentido para el tratamiento de células madre tumorales
|
JP2016519083A
(ja)
|
2013-03-14 |
2016-06-30 |
アンデス バイオテクノロジーズ ソシエダード アノニマAndes Biotechnologies S.A. |
多発性骨髄腫を検出および処置するための方法
|
RS56663B1
(sr)
|
2013-03-14 |
2018-03-30 |
Alnylam Pharmaceuticals Inc |
Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
|
US20140283211A1
(en)
|
2013-03-14 |
2014-09-18 |
Monsanto Technology Llc |
Methods and Compositions for Plant Pest Control
|
US10568328B2
(en)
|
2013-03-15 |
2020-02-25 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いたゲノム編集の治療的使用
|
CN105378085B
(zh)
|
2013-05-01 |
2019-02-15 |
Ionis制药公司 |
用于调节hbv和ttr表达的组合物和方法
|
AU2014268529C1
(en)
|
2013-05-22 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
TMPRSS6 iRNA compositions and methods of use thereof
|
SG10201804472YA
(en)
|
2013-05-22 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP3004396B1
(de)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Zusammensetzungen zur krebsbehandlung
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
CA2918387C
(en)
|
2013-07-19 |
2021-11-02 |
Monsanto Technology Llc |
Compositions and methods for controlling leptinotarsa
|
US9850496B2
(en)
|
2013-07-19 |
2017-12-26 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
US10894963B2
(en)
|
2013-07-25 |
2021-01-19 |
Exicure, Inc. |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
PT3041854T
(pt)
|
2013-08-08 |
2020-03-05 |
Scripps Research Inst |
Um método para a identificação enzimática específica ao local de ácidos nucleicos in vitro pela incorporação de nucleótidos não-naturais
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
NZ757749A
(en)
|
2013-10-04 |
2022-07-01 |
Icahn School Med Mount Sinai |
Compositions and methods for inhibiting expression of the alas1 gene
|
WO2015051045A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
|
EP3052107B1
(de)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organische verbindungen zur behandlung von hepatitis-b-infektionen
|
US10584387B2
(en)
|
2013-10-09 |
2020-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
US9758546B2
(en)
|
2013-10-21 |
2017-09-12 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
CA2928779A1
(en)
|
2013-10-21 |
2015-04-30 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
US10301622B2
(en)
|
2013-11-04 |
2019-05-28 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
|
NZ719544A
(en)
|
2013-11-04 |
2022-09-30 |
Beeologics Inc |
Compositions and methods for controlling arthropod parasite and pest infestations
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
癌の免疫療法
|
JP6527516B2
(ja)
|
2013-12-03 |
2019-06-05 |
ノースウェスタン ユニバーシティ |
リポソーム粒子、前述のものを作製する方法及びその使用
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
UA119253C2
(uk)
|
2013-12-10 |
2019-05-27 |
Біолоджикс, Інк. |
Спосіб боротьби із вірусом у кліща varroa та у бджіл
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
US10900083B2
(en)
|
2013-12-20 |
2021-01-26 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
WO2015108982A2
(en)
|
2014-01-15 |
2015-07-23 |
Monsanto Technology Llc |
Methods and compositions for weed control using epsps polynucleotides
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN111733231A
(zh)
|
2014-02-05 |
2020-10-02 |
耶达研究及发展有限公司 |
用于治疗和诊断的微rna和包含所述微rna的组合物
|
EP3960860A3
(de)
|
2014-02-11 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3119789B1
(de)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
SG10201808063PA
(en)
|
2014-03-19 |
2018-10-30 |
Ionis Pharmaceuticals Inc |
Compositions for modulating ataxin 2 expression
|
EP3420809A1
(de)
|
2014-04-01 |
2019-01-02 |
Monsanto Technology LLC |
Zusammensetzungen und verfahren zur bekämpfung von insektenbefall
|
MX2016012922A
(es)
|
2014-04-01 |
2017-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones para modular la expresion de sod-1.
|
WO2015157555A2
(en)
|
2014-04-09 |
2015-10-15 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
WO2015168108A2
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic targeting mdm2 or mycn
|
PE20190626A1
(es)
|
2014-05-01 |
2019-04-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
WO2015168514A1
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
CN112852809A
(zh)
|
2014-05-22 |
2021-05-28 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
KR20170031668A
(ko)
|
2014-06-02 |
2017-03-21 |
칠드런'즈 메디컬 센터 코포레이션 |
면역 조절을 위한 방법 및 조성물
|
KR102524543B1
(ko)
|
2014-06-10 |
2023-04-20 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드
|
CN106795515B
(zh)
|
2014-06-23 |
2021-06-08 |
孟山都技术公司 |
用于经由rna干扰调控基因表达的组合物和方法
|
US10301624B2
(en)
|
2014-06-25 |
2019-05-28 |
The General Hospital Corporation |
Targeting human satellite II (HSATII)
|
EP3161138A4
(de)
|
2014-06-25 |
2017-12-06 |
Monsanto Technology LLC |
Verfahren und zusammensetzungen zur zuführung von nukleinsäuren an pflanzenzellen und regulierung der genexpression
|
KR102569494B1
(ko)
|
2014-07-15 |
2023-08-21 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
Cd44의 단리된 폴리펩타이드 및 이의 사용
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
WO2016018887A1
(en)
|
2014-07-29 |
2016-02-04 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
IL250302B
(en)
|
2014-07-31 |
2022-07-01 |
Uab Research Foundation |
Apoe mimetic peptides with high potency to clear plasma cholesterol
|
US20170232109A1
(en)
|
2014-08-19 |
2017-08-17 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
WO2016030899A1
(en)
|
2014-08-28 |
2016-03-03 |
Yeda Research And Development Co. Ltd. |
Methods of treating amyotrophic lateral scleroses
|
WO2016033326A2
(en)
|
2014-08-29 |
2016-03-03 |
Alnylam Pharmaceuticals, Inc. |
Methods of treating transthyretin (ttr) mediated amyloidosis
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
US10385343B2
(en)
|
2014-08-29 |
2019-08-20 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
KR20230037676A
(ko)
|
2014-09-05 |
2023-03-16 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
EP3663403A1
(de)
|
2014-09-26 |
2020-06-10 |
University of Massachusetts |
Rna-modulierende stoffe
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3904519A1
(de)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
KR20170078843A
(ko)
|
2014-11-21 |
2017-07-07 |
노오쓰웨스턴 유니버시티 |
구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
|
EP3230445B1
(de)
|
2014-12-12 |
2024-01-24 |
Tod M. Woolf |
Zusammensetzungen und verfahren zur editierung von nukleinsäuren in zellen mit oligonukleotiden
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
US10968449B2
(en)
|
2015-01-22 |
2021-04-06 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
JP2018506715A
(ja)
|
2015-01-23 |
2018-03-08 |
ヴァンダービルト ユニバーシティー |
堅固なインターフェロメーター及びその使用方法
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
EP3256587A2
(de)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing-3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3262173A2
(de)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
|
EP3262181B1
(de)
|
2015-02-23 |
2024-04-10 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur flüssigphasendetritylierung von oligomeren verbindungen
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
WO2016142948A1
(en)
|
2015-03-11 |
2016-09-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Decoy oligonucleotides for the treatment of diseases
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
EP3273971A4
(de)
|
2015-03-27 |
2018-12-05 |
Yeda Research and Development Co. Ltd. |
Verfahren zur behandlung von motoneuronenerkrankungen
|
CN107847524A
(zh)
|
2015-03-27 |
2018-03-27 |
哈佛学院校长同事会 |
经过修饰的t细胞及其制备和使用方法
|
EP3283502A4
(de)
|
2015-04-07 |
2019-04-03 |
The General Hospital Corporation |
Verfahren zur reaktivierung von genen auf dem inaktiven x-chromosom
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
US10907152B2
(en)
|
2015-05-04 |
2021-02-02 |
Monsanto Technology Llc |
Compositions and methods for controlling arthropod parasite and pest infestations
|
US10898505B2
(en)
|
2015-05-06 |
2021-01-26 |
Benitec Biopharma Limited |
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
|
WO2016181393A1
(en)
|
2015-05-11 |
2016-11-17 |
Yeda Research And Development Co. Ltd. |
Citrin inhibitors for the treatment of cancer
|
UY36703A
(es)
|
2015-06-02 |
2016-12-30 |
Monsanto Technology Llc |
Composiciones y métodos para la administración de un polinucleótido en una planta
|
AU2016270913A1
(en)
|
2015-06-03 |
2018-01-04 |
Monsanto Technology Llc |
Methods and compositions for introducing nucleic acids into plants
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
US20180188257A1
(en)
|
2015-06-19 |
2018-07-05 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
EP3314250A4
(de)
|
2015-06-26 |
2018-12-05 |
Beth Israel Deaconess Medical Center, Inc. |
Auf tetraspanin 33 (tspann33) in myeloidabgeleiteten suppressorzellen abzielende krebstherapie
|
CA2991045A1
(en)
|
2015-06-29 |
2017-01-05 |
Caris Science, Inc. |
Therapeutic oligonucleotides binding c1q
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
WO2017019918A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
US20180221393A1
(en)
|
2015-08-03 |
2018-08-09 |
Biokine Therapeutics Ltd. |
Cxcr4 binding agents for treatment of diseases
|
WO2017021961A1
(en)
|
2015-08-04 |
2017-02-09 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
WO2017027350A2
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
EP3344769B1
(de)
|
2015-09-02 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna-kompositionen und methoden zu deren verwendung
|
US10070118B2
(en)
*
|
2015-09-17 |
2018-09-04 |
Lumii, Inc. |
Multi-view displays and associated systems and methods
|
WO2017064546A1
(en)
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
EP3368063B1
(de)
|
2015-10-28 |
2023-09-06 |
Vertex Pharmaceuticals Inc. |
Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
CA2999649A1
(en)
|
2015-11-06 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1a
|
WO2017081686A1
(en)
|
2015-11-10 |
2017-05-18 |
B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University |
Means and methods for reducing tumorigenicity of cancer stem cells
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
PT3380613T
(pt)
|
2015-11-23 |
2022-12-02 |
Univ California |
Deteção e manipulação de arn celular através da administração nuclear de crispr/cas9
|
JP6932698B2
(ja)
|
2015-12-01 |
2021-09-08 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
アルファ1アンチトリプシン欠乏症の治療のための材料および方法
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
JP6947729B2
(ja)
|
2015-12-23 |
2021-10-13 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
筋萎縮性側索硬化症及び/または前頭側頭葉変性症の治療のための材料及び方法
|
US10907160B2
(en)
|
2016-01-05 |
2021-02-02 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
US10627396B2
(en)
|
2016-01-29 |
2020-04-21 |
Vanderbilt University |
Free-solution response function interferometry
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3416689B1
(de)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
|
JP7033072B2
(ja)
|
2016-02-25 |
2022-03-09 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
Smoc2を標的化する線維症のための治療方法
|
EP3423581A4
(de)
|
2016-03-04 |
2020-03-04 |
Rhode Island Hospital |
Targeting von mikrorna zur krebsbehandlung
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
EP3429632B1
(de)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von erblicher haemochromatose
|
KR20190008843A
(ko)
|
2016-03-18 |
2019-01-25 |
카리스 싸이언스, 인코포레이티드 |
올리고뉴클레오티드 프로브 및 이의 용도
|
NZ747314A
(en)
|
2016-04-14 |
2022-07-29 |
Benitec Ip Holdings Inc |
Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
|
MX2018012729A
(es)
|
2016-04-18 |
2019-07-04 |
Crispr Therapeutics Ag |
Materiales y metodos para el tratamiento de hemoglobinopatias.
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US11293017B2
(en)
|
2016-05-25 |
2022-04-05 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
WO2017223528A1
(en)
|
2016-06-24 |
2017-12-28 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
EP3478829A1
(de)
|
2016-06-29 |
2019-05-08 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von myotoner dystrophie typ 1 (dm1) und anderen erkrankungen
|
AU2017290614C1
(en)
|
2016-06-29 |
2024-01-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
EP3478313B1
(de)
|
2016-06-29 |
2022-05-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von amyotropher lateralsklerose (als) und anderen verwandten erkrankungen
|
US11801313B2
(en)
|
2016-07-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
AU2017296195A1
(en)
|
2016-07-11 |
2019-01-24 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
JP2019520844A
(ja)
|
2016-07-21 |
2019-07-25 |
マックスサイト インコーポレーティッド |
ゲノムdnaを改変するための方法および組成物
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
KR102493872B1
(ko)
|
2016-09-02 |
2023-01-30 |
다이서나 파마수이티컬, 인크. |
4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
EP3330276A1
(de)
|
2016-11-30 |
2018-06-06 |
Universität Bern |
Neuartige bicyclische nukleoside und daraus hergestellte oligomere
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
EP3555296A4
(de)
|
2016-12-13 |
2020-07-29 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Verfahren zur exogenen wirkstoffaktivierung von chemisch induzierten signalisierungskomplexen, die in vitro und in vivo in manipulierten zellen exprimiert werden
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
GB201700595D0
(en)
*
|
2017-01-13 |
2017-03-01 |
Univ Oxford Innovation Ltd |
Oligonucleotide ligation
|
JP7458785B2
(ja)
|
2017-01-23 |
2024-04-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒドロキシステロイド17-βデヒドロゲナーゼ13(HSD17B13)バリアント及びその使用
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
EP3585898A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von spinozerebellärer ataxie typ 1 (sca1) und anderen mit dem gen des proteins von spinozerebellärer ataxie typ 1 (atxn1) assoziierten erkrankungen oder störungen
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
US20180284123A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
|
BR112019021852A2
(pt)
|
2017-04-18 |
2020-06-02 |
Alnylam Pharmaceuticals, Inc. |
Agente de rnai e uma vacina contra hbv, uso ou método e kit para tratamento
|
EP4036101A1
(de)
|
2017-04-20 |
2022-08-03 |
Synthena AG |
Modifizierte oligomere verbindungen mit tricyclischen dna-nukleosiden und verwendungen davon
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
US11767520B2
(en)
|
2017-04-20 |
2023-09-26 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
AU2018367896B2
(en)
|
2017-05-12 |
2023-06-01 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
AR112756A1
(es)
|
2017-07-11 |
2019-12-11 |
Synthorx Inc |
Incorporación de nucleótidos no naturales, y su método
|
CA3069868A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
EP3652186A4
(de)
|
2017-07-13 |
2021-03-31 |
Northwestern University |
Allgemeines und direktes verfahren zur herstellung von oligonukleotidfunktionalisierten metallorganischen gerüstnanopartikeln
|
EP3661955A4
(de)
|
2017-08-03 |
2021-05-26 |
Synthorx, Inc. |
Cytokin-konjugate zur behandlung von autoimmunerkrankungen
|
WO2019032896A1
(en)
|
2017-08-09 |
2019-02-14 |
Lumii, Inc. |
MANUFACTURE OF LIGHT FIELD PRINTS
|
EP3668984A4
(de)
|
2017-08-18 |
2021-09-08 |
Ionis Pharmaceuticals, Inc. |
Modulation des notch-signalweges zur behandlung von atemwegserkrankungen
|
GB201714403D0
(en)
*
|
2017-09-07 |
2017-10-25 |
Univ Oxford Innovation Ltd |
Process for oligonucleotide synthesis
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
MA50833A
(fr)
|
2017-10-17 |
2020-08-26 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique pour l'hémophilie a
|
MA50849A
(fr)
|
2017-10-26 |
2020-09-02 |
Vertex Pharma |
Substances et procédés pour le traitement d'hémoglobinopathies
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
US20210363521A1
(en)
|
2017-11-09 |
2021-11-25 |
Vertex Pharmaceuticals Incorporated |
CRISPR/CAS Systems For Treatment of DMD
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
EP3710587A1
(de)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
US20190153440A1
(en)
|
2017-11-21 |
2019-05-23 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
WO2019113149A1
(en)
|
2017-12-05 |
2019-06-13 |
Crispr Therapeutics Ag |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
CA3086343A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
CA3084633A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
MA51637A
(fr)
|
2018-01-12 |
2020-11-18 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique par ciblage de la transferrine
|
TW201934129A
(zh)
|
2018-01-15 |
2019-09-01 |
美商Ionis製藥公司 |
Dnm2表現之調節劑
|
US20200369639A1
(en)
|
2018-01-19 |
2020-11-26 |
Synthena Ag |
Tricyclo-dna nucleoside precursors and processes for preparing the same
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
EP3749767A1
(de)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
MA51788A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes pour traiter des hémoglobinopathies
|
EP3749368A1
(de)
|
2018-02-08 |
2020-12-16 |
Yeda Research and Development Co. Ltd |
Verfahren zur identifizierung und verwendung von mitteln zur behandlung von mit darmbarrierefunktionsstörungen einhergehenden krankheiten
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
WO2019165453A1
(en)
|
2018-02-26 |
2019-08-29 |
Synthorx, Inc. |
Il-15 conjugates and uses thereof
|
TW202000199A
(zh)
|
2018-03-02 |
2020-01-01 |
美商Ionis製藥公司 |
Irf4 表現之調節劑
|
EP3759127A4
(de)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins
|
JP7417529B2
(ja)
|
2018-03-07 |
2024-01-18 |
サノフイ |
ヌクレオチド前駆体、ヌクレオチド類似体およびこれを含むオリゴマー化合物
|
AU2019239957A1
(en)
|
2018-03-19 |
2020-09-10 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and uses thereof
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
US20210147847A1
(en)
|
2018-03-30 |
2021-05-20 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
WO2019195738A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
SG11202010012PA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fxi expression
|
CA3098144A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
MX2020013653A
(es)
|
2018-06-27 |
2021-03-02 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de lrrk2.
|
CN112585268A
(zh)
|
2018-06-28 |
2021-03-30 |
克里斯珀医疗股份公司 |
通过插入供体多核苷酸用于基因组编辑的组合物和方法
|
TW202020154A
(zh)
|
2018-07-25 |
2020-06-01 |
美商Ionis製藥公司 |
用於減少atxn2表現之化合物及方法
|
AR114551A1
(es)
|
2018-08-13 |
2020-09-16 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
WO2020047229A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
AU2019339509A1
(en)
|
2018-09-14 |
2021-05-13 |
Northwestern University |
Programming protein polymerization with DNA
|
AU2019344776A1
(en)
|
2018-09-18 |
2021-01-21 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
US20210348159A1
(en)
|
2018-10-17 |
2021-11-11 |
Crispr Therapeutics Ag |
Compositions and methods for delivering transgenes
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
US11208650B2
(en)
|
2018-11-15 |
2021-12-28 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
IL263184A
(en)
|
2018-11-21 |
2020-05-31 |
Yarden Yosef |
Method of treating cancer and compositions for same
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
CA3122402A1
(en)
|
2018-12-20 |
2020-06-25 |
Vir Biotechnology, Inc. |
Combination hbv therapy
|
US20220056455A1
(en)
|
2018-12-20 |
2022-02-24 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
CN114949240A
(zh)
|
2019-02-06 |
2022-08-30 |
新索思股份有限公司 |
Il-2缀合物及其使用方法
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
EP3927378A1
(de)
|
2019-02-21 |
2021-12-29 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Verfahren zur reduktion von arzneimittelinduzierter nephrotoxizität
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
MA55297A
(fr)
|
2019-03-12 |
2022-01-19 |
Bayer Healthcare Llc |
Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations
|
SG11202110679YA
(en)
|
2019-03-29 |
2021-10-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating ube3a-ats
|
CN113924365A
(zh)
|
2019-03-29 |
2022-01-11 |
迪克纳制药公司 |
用于治疗kras相关疾病或病症的组合物和方法
|
US20220177880A1
(en)
|
2019-05-03 |
2022-06-09 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
EP3966327A1
(de)
|
2019-05-08 |
2022-03-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two-vektorsystemen zur behandlung von dmd
|
MX2021013698A
(es)
|
2019-05-13 |
2021-12-10 |
Vir Biotechnology Inc |
Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb).
|
JP2022538784A
(ja)
|
2019-06-14 |
2022-09-06 |
ザ スクリプス リサーチ インスティテュート |
半合成生物における複製、転写および翻訳のための試薬ならびに方法
|
US20210008161A1
(en)
|
2019-06-17 |
2021-01-14 |
Crispr Therapeutics Ag |
Methods and compositions for improved homology directed repair
|
EP3956450A4
(de)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation von gfap
|
EP4007812A1
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
|
EP4007811A2
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4013454A1
(de)
|
2019-08-15 |
2022-06-22 |
Synthorx, Inc. |
Immunonkologische kombinationstherapien mit il-2-konjugaten
|
CN114555621A
(zh)
|
2019-08-15 |
2022-05-27 |
Ionis制药公司 |
键修饰的寡聚化合物及其用途
|
US20210054040A1
(en)
|
2019-08-23 |
2021-02-25 |
Synthorx, Inc. |
Novel il-15 conjugates and uses thereof
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
AU2020347154A1
(en)
|
2019-09-10 |
2022-03-03 |
Synthorx, Inc. |
IL-2 conjugates and methods of use to treat autoimmune diseases
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
EP4048793A1
(de)
|
2019-10-22 |
2022-08-31 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
CA3155921A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2020380275A1
(en)
|
2019-11-04 |
2022-04-14 |
Synthorx, Inc. |
Interleukin 10 conjugates and uses thereof
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
AU2020391215A1
(en)
|
2019-11-27 |
2022-06-02 |
Bayer Healthcare Llc |
Methods of synthesizing RNA molecules
|
CN115151641A
(zh)
|
2019-12-13 |
2022-10-04 |
阿尔尼拉姆医药品有限公司 |
人类染色体9开放阅读框72(C9ORF72)iRNA剂组合物及其使用方法
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2021122944A1
(en)
|
2019-12-18 |
2021-06-24 |
Alia Therapeutics Srl |
Compositions and methods for treating retinitis pigmentosa
|
WO2021146488A1
(en)
|
2020-01-15 |
2021-07-22 |
Dicerna Pharmaceuticals, Inc. |
4'-o-methylene phosphonate nucleic acids and analogues thereof
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
BR112022015770A2
(pt)
|
2020-02-10 |
2022-10-11 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciar a expressão de vegf-a
|
IL295496A
(en)
|
2020-02-18 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna preparations and methods of using them
|
US20220064638A1
(en)
|
2020-02-28 |
2022-03-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating smn2
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
JP2023516095A
(ja)
|
2020-03-06 |
2023-04-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
EP4127171A2
(de)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
|
TW202204618A
(zh)
|
2020-04-06 |
2022-02-01 |
美商艾爾妮蘭製藥公司 |
用於靜默myoc表現之組合物及方法
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
WO2021222065A1
(en)
|
2020-04-27 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
JP2023523790A
(ja)
|
2020-04-30 |
2023-06-07 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体因子B(CFB)iRNA組成物およびその使用方法
|
CA3181546A1
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
EP4150090A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
EP4150088A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4161552A1
(de)
|
2020-06-05 |
2023-04-12 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur behandlung von neoplasien
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
JP2023530461A
(ja)
|
2020-06-18 |
2023-07-18 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
キサンチンデヒドロゲナーゼ(XDH)iRNA組成物およびその使用方法
|
WO2021262840A1
(en)
|
2020-06-24 |
2021-12-30 |
Vir Biotechnology, Inc. |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
CA3183834A1
(en)
|
2020-06-25 |
2021-12-30 |
Giovanni Abbadessa |
Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
|
MX2022016338A
(es)
|
2020-06-29 |
2023-01-24 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la plp1.
|
EP4192505A1
(de)
|
2020-08-04 |
2023-06-14 |
Dicerna Pharmaceuticals, Inc. |
Systemische verabreichung von oligonukleotiden
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022070107A1
(en)
|
2020-09-30 |
2022-04-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
BR112023006364A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
|
WO2022076859A1
(en)
|
2020-10-09 |
2022-04-14 |
Synthorx, Inc. |
Immuno oncology therapies with il-2 conjugates
|
EP4228637A1
(de)
|
2020-10-15 |
2023-08-23 |
Yeda Research and Development Co. Ltd |
Verfahren zur behandlung von myeloidmalignitäten
|
JP2023546199A
(ja)
|
2020-10-20 |
2023-11-01 |
サノフイ |
アシアロ糖タンパク質受容体のための新規リガンド
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
Coagulation factor iRNA compositions (F5) and methods of using them
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4267732A1
(de)
|
2020-12-23 |
2023-11-01 |
Flagship Pioneering Innovations VI, LLC |
Zusammensetzungen aus modifizierten tremen und verwendungen davon
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
EP4291243A1
(de)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lungenkrebskombinationstherapie mit il-2-konjugaten und einem anti-pd-1-antikörper oder antigenbindendem fragment davon
|
TW202305131A
(zh)
|
2021-02-12 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
用於治療或預防超氧歧化酶1-(SOD1-)相關的神經退化疾病的超氧歧化酶1(SOD1)iRNA組成物及其使用方法
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
BR112023016645A2
(pt)
|
2021-02-26 |
2023-11-14 |
Alnylam Pharmaceuticals Inc |
Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
|
TW202302849A
(zh)
|
2021-03-04 |
2023-01-16 |
美商艾拉倫製藥股份有限公司 |
類血管生成素3(ANGPTL3)iRNA組成物及其使用方法
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
AR125230A1
(es)
|
2021-03-29 |
2023-06-28 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
EP4314293A1
(de)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
TW202309280A
(zh)
|
2021-04-26 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
跨膜絲胺酸蛋白酶6(TMPRSS6)iRNA組成物及其使用方法
|
EP4330396A1
(de)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4334448A1
(de)
|
2021-05-03 |
2024-03-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
|
EP4341401A1
(de)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2022256538A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
AU2022283796A1
(en)
|
2021-06-04 |
2023-11-09 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
CA3222950A1
(en)
|
2021-06-11 |
2022-12-15 |
Bayer Aktiengesellschaft |
Type v rna programmable endonuclease systems
|
EP4355759A1
(de)
|
2021-06-18 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur reduzierung der ifnar1-expression
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
WO2023003995A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
TW202328445A
(zh)
|
2021-08-03 |
2023-07-16 |
美商艾拉倫製藥股份有限公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其使用方法
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
AU2022328347A1
(en)
|
2021-08-13 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023177866A1
(en)
|
2022-03-18 |
2023-09-21 |
Dicerna Pharmaceuticals, Inc. |
Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|